European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility
An erratum to this article was published (Br J Anaesth, Oct 2026 ↗)
Methodological detailsconsensus
- Consensus
Recommendations
As issued by the authors
New diagnostic designation, the malignant hyperthermia (MH) genotype, introduced in addition to classification of MH susceptibility by the in vitro halothane/caffeine contracture test
Revised diagnostic pathways include the adapted European Malignant Hyperthermia Group curation system for classifying genetic variants by relevance to MH
Minor changes to the in vitro halothane/caffeine contracture test protocol; updated patient referral criteria and clinical interpretation of diagnostic results
First consensus definition of a clinical MH event
Original publication
European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility. Br J Anaesth. Published 1 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →